Latest Pancreatic Cancer News

Page 6 of 7
Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.
Ada Torres
Ada Torres
23 July 2025
Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.
Ada Torres
Ada Torres
23 July 2025
Amplia Therapeutics has secured US ethics approval to launch a Phase 2 trial combining its drug narmafotinib with FOLFIRINOX chemotherapy for advanced pancreatic cancer, marking a key step in its clinical development.
Ada Torres
Ada Torres
24 June 2025
Amplia Therapeutics has announced a second confirmed complete response in its ACCENT trial for advanced pancreatic cancer, a notably rare achievement in this challenging disease.
Ada Torres
Ada Torres
19 June 2025
Amplia Therapeutics has reported a rare pathological complete response in a patient from its ACCENT trial, highlighting promising potential for its drug narmafotinib in treating advanced pancreatic cancer.
Ada Torres
Ada Torres
16 June 2025
OncoSil Medical has launched a Security Purchase Plan offering discounted shares and free options to eligible shareholders, aiming to accelerate commercialization of its pancreatic cancer treatment device.
Ada Torres
Ada Torres
4 June 2025
Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.
Ada Torres
Ada Torres
30 May 2025
OncoSil Medical has secured $8.7 million through a placement and share purchase plan to fund commercialization of its pancreatic cancer treatment device, aiming for positive cash flow by mid-2026. Near-completion clinical trials could soon unlock broader market access.
Ada Torres
Ada Torres
26 May 2025
Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.
Ada Torres
Ada Torres
15 May 2025
Amplia Therapeutics has completed recruitment early for its Phase 2a ACCENT trial in advanced pancreatic cancer, reporting encouraging interim results and advancing a second trial with FDA-backed protocol changes.
Ada Torres
Ada Torres
30 Apr 2025
OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.
Ada Torres
Ada Torres
29 Apr 2025
OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.
Victor Sage
Victor Sage
4 Feb 2025

Browse the archive

Full archive